Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [906]

Omics, early detection and novel therapies: Epigenetic studies

Dr Adele Murrell - University of Bath, Bath, UK

Omics, early detection and novel therapies: Epigenetic studies ( Dr Adele Murrell - University of Bath, Bath, UK )

Small cell lung cancer: Q & A

Prof Gordon McVie, Prof Caroline Dive, Dr Fiona Blackhall and Dr Marianne...

Small cell lung cancer: Q & A ( Prof Gordon McVie, Prof Caroline Dive, Dr Fiona Blackhall and Dr Marianne Nicolson )

Small cell lung cancer: New therapies

Dr Fiona Blackhall - The Christie NHS Foundation Trust, Manchester, UK

Small cell lung cancer: New therapies ( Dr Fiona Blackhall - The Christie NHS Foundation Trust, Manchester, UK )

Small cell lung cancer: Current standards of care

Dr Marianne Nicolson - Aberdeen Royal Infirmary, Aberdeen, UK

Small cell lung cancer: Current standards of care ( Dr Marianne Nicolson - Aberdeen Royal Infirmary, Aberdeen, UK )

Maintenance in NSCLC: Q & A

Dr Besse and Dr Bhosle

Maintenance in NSCLC: Q & A ( Dr Besse and Dr Bhosle )

Maintenance in NSCLC: Arguments for

Dr Jaishree Bhosle - The Royal Marsden NHS Foundation Trust, London, UK

Maintenance in NSCLC: Arguments for ( Dr Jaishree Bhosle - The Royal Marsden NHS Foundation Trust, London, UK )

Maintenance in NSCLC: Arguments against

Dr Benjamin Besse - Institut Gustave Roussy, Paris, France

Maintenance in NSCLC: Arguments against ( Dr Benjamin Besse - Institut Gustave Roussy, Paris, France )

We should use PDL1 and other biomarkers for selecting patients for immune...

Dr Mary O’Brien - The Royal Marsden NHS Foundation Trust, London, UK

We should use PDL1 and other biomarkers for selecting patients for immune checkpoint therapies ( Dr Mary O’Brien - The Royal Marsden NHS Foundation Trust, London, UK )

We should not use PDL1 and other biomarkers for selecting patients for immune...

Prof Gordon McVie - King's College London, London, UK

We should not use PDL1 and other biomarkers for selecting patients for immune checkpoint therapies ( Prof Gordon McVie - King's College London, London, UK )

Using PDL1 and other biomarkers in patient selection for immunology: Q & A

Dr O'Brien and Prof McVie

Using PDL1 and other biomarkers in patient selection for immunology: Q & A ( Dr O'Brien and Prof McVie )

Current standards of care in advanced NSCLC

Dr Frances Shepherd - The Princess Margaret Cancer Centre, Toronto, Canada

Current standards of care in advanced NSCLC ( Dr Frances Shepherd - The Princess Margaret Cancer Centre, Toronto, Canada )

Imaging and novel PET tracers: Q & A

Dr Giulia Veronesi and Prof Tony Ng

Imaging and novel PET tracers: Q & A ( Dr Giulia Veronesi and Prof Tony Ng )

More from ecancer